35 completed, 9 terminated, 8 unknown, 5 recruiting. 60 Phase 3, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 60 | Completed 35, Terminated 9, Unknown 8, Recruiting 5, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 15 | Terminated 4, Unknown 4, Completed 3, Recruiting 3, Active not recruiting 1 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-12-24 | 2026-02-05 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-03-01 | 2026-03-10 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin bevacizumab with oral curcumin, bevacizumab with oral placebo - Diabetic Macular Edema, Macular Edema | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 52 | 2021-10-10 | 2024-09-19 |
| Corneal Crosslinking for Treatment of Corneal Neovascularization 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1% - Corneal Neovascularization | Phase 2 / Phase 3 | Recruiting | Price Vision Group | 138 | 2021-05-03 | 2026-09-17 |
| A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration RTH258/Brolucizumab - Neovascular Age Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 210 | 2021-01-26 | 2024-10-09 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
| An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study brolucizumab - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 248 | 2020-12-16 | 2024-10-09 |
| Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration RTH258/Brolucizumab - Neovascular Age-Related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 295 | 2020-12-14 | 2024-11-07 |
| Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy Brolucizumab 6 mg, Panretinal photocoagulation laser - Proliferative Diabetic Retinopathy | Phase 3 | Completed | Novartis Pharmaceuticals | 689 | 2020-11-19 | 2025-10-16 |
| Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Brolucizumab 6 mg, Aflibercept 2 mg - Age-related Macular Degeneration | Phase 3 | Completed | Novartis Pharmaceuticals | 734 | 2019-09-25 | 2024-10-09 |
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
| Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Squalamine lactate ophthalmic solution, 0.2%, Placebo Ophthalmic solution, ranibizumab - Age-related Macular Degeneration | Phase 3 | Unknown | Ohr Pharmaceutical Inc. | 230 | 2016-04-12 | 2017-04-27 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution - Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Alcon Research | 1048 | 2015-07-28 | 2025-01-16 |
| Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution - Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Alcon Research | 1775 | 2014-12-08 | 2025-01-16 |
| A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Ranibizumab - Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | Novartis Pharmaceuticals | 200 | 2014-06-10 | 2019-02-18 |
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 645 | 2014-05-01 | 2024-10-31 |
Showing 20 of 60. Sign in to see all of them.
Choroidal Neovascularization (47) · Macular Degeneration (33) · Wet Macular Degeneration (7) · Eye Diseases (6) · Vision Disorders (6) · Neovascularization, Pathologic (5) · Polypoidal Choroidal Vasculopathy (5) · Retinal Diseases (5) · Geographic Atrophy (4) · Retinal Neovascularization (4) · Diabetic Retinopathy (3) · Myopia, Degenerative (3) · Retinal Degeneration (3) · Angioid Streaks (2) · Corneal Neovascularization (2)
Pathologic Processes (60) · Pathological Conditions, Signs and Symptoms (60) · Neovascularization, Pathologic (55) · Eye Diseases (53) · Choroid Diseases (51) · Uveal Diseases (51) · Retinal Diseases (38) · Retinal Degeneration (32) · Cardiovascular Diseases (7) · Nervous System Diseases (7) · Neurologic Manifestations (7) · Sensation Disorders (7) · Signs and Symptoms (7) · Vascular Diseases (6)
Ranibizumab (20) · Bevacizumab (9) · aflibercept (9) · brolucizumab (8) · Verteporfin (6) · E10030 aptamer (3) · Photochemotherapy (3) · salicylhydroxamic acid (3) · Triamcinolone Acetonide (2) · 1-phenyl-3,3-dimethyltriazene (1) · Atorvastatin (1) · Curcumin (1) · Exercise (1) · Glucose (1) · Intravitreal Injections (1)
Novartis Pharmaceuticals (13) · Asociación para Evitar la Ceguera en México (4) · National Eye Institute (NEI) (4) · Novartis (4) · Ophthotech Corporation (3) · AbbVie (2) · Alcon Research (2) · EyeBiotech Ltd. (2) · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (2) · Medical University of Vienna (2) · Yeungnam University College of Medicine (2) · Bayer (1) · Biocad (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Eyetech Pharmaceuticals (1)
United States (20) · Spain (13) · France (12) · Italy (12) · South Korea (12) · Canada (10) · Germany (10) · Switzerland (10) · Hungary (8) · Australia (7) · Portugal (7) · United Kingdom (7) · Austria (6) · Brazil (6) · Czechia (6)
Anne C Odergren, MD (1) · Avner Ingerman, MD (1) · Chong-Lye Ang, FRCOphth (1) · Daniel F Martin, MD (1) · David J Wilson, MD (1) · David Wong, MD (1) · Douglas A Jabs, MD, MBA (1)
PMID 30957581, PMID 30986442, PMID 32374423, PMID 33207259, PMID 34968756, PMID 37343623, PMID 39033924, PMID 11071039, PMID 11741106, PMID 12707595, PMID 14557174, PMID 16765697, PMID 16897221, PMID 17659962, PMID 19506188, PMID 19643495, PMID 19726427, PMID 20375343, PMID 21526923, PMID 22150050, PMID 22382503, PMID 22424834, PMID 22426346, PMID 22444829, PMID 22452699, PMID 22512984, PMID 22555112, PMID 22939114, PMID 23047002, PMID 23337555, PMID 23352196, PMID 23642377, PMID 23706946, PMID 24084496, PMID 24314839, PMID 24326106, PMID 24652518, PMID 24727261, PMID 24835760, PMID 24875610, PMID 24949820, PMID 25064723, PMID 25079064, PMID 25109929, PMID 25220133, PMID 25307130, PMID 25542520, PMID 25600198, PMID 25646029, PMID 25824327
2019 (3), 2014 (1), U10EY017823 (1)